there is reason why BIT have limited institutional shareholders because BIT is too risky! High risk of failure
How are BiT going to fund progression to regulatory end point and ultimately approval. BIT do not have enough cash IMO.
BIT spoke about phase 3 how many months ago! Lol joke! they haven’t even got to the end of phase 2 (what letter of the alphabet are we now on?).
Clinical trials (recruitment, data recording, data analysis, third party testing, third party audits, etc, etc) are expensive…can BIT fund it all with current cash reserves!? I think not! Who will provide the capital injection and at what opportunity price?
BIT is a disappointment and I think it start with administration and a board that lacks independence
BIT Price at posting:
5.2¢ Sentiment: None Disclosure: Held
